Charles River Laboratories has entered into an exclusive partnership with Fios Genomics, a provider of bioinformatics data analysis services.
Through this partnership, Charles River clients will have access to Fios Genomics’ knowledge in bioinformatics, statistics and biology to assist in the sourcing and analysis of the high-dimensional, multi-variant datasets associated with drug development including microarrays, next-generation sequencing (NGS), proteomics, metabolomics and epigenetics as well as the associated meta-data.
The biologically-relevant insights revealed by the team at Fios Genomics, combined with Charles River’s integrated drug discovery and development platform and the scientific expertise of both organizations, will enable Charles River clients to make more data-driven decisions about their programs, improving both confidence and speed.
“The explosion in -omics data has been a boon for the drug discovery industry, but analysis and interpretation of these datasets are challenging. Through our partnership with Fios Genomics, Charles River clients will have greater access to the special combination of skills in bioinformatics, statistics and biology required to obtain meaningful information from their data,” Birgit Girshick, Corporate Executive Vice President, Discovery & Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services at Charles River said.
“Our approach to bioinformatics at Fios Genomics is to look beyond algorithms and statistics and understand that biological relevance and statistical significance are not necessarily the same thing,” Sarah Lynagh, PhD, Chief Executive Officer at Fios Genomics said. “Bioinformatics is about biology, outcome and pathways, and by partnering with Charles River, we can help more researchers make data-driven decisions about their programs that are grounded in biological insights.”